EU-Wi d e Cross-Section a l Obser v at i o n al Study of Lipid-Modifying Therapy Use in Se c ondary and Pr i mary Care: the DA VINCI study
Open accessThe DOI matches its Crossref record; 10 of the 10 references it cites were found in a registry or an index.
Abstract
Aims: To provide contemporary data on the implementation of European guideline recommendations for lipid-lowering therapies (LLTs) across different settings and populations and how this impacts low-density lipoprotein cholesterol (LDL-C) goal achievement. Methods and results: An 18 country, cross-sectional, observational study of patients prescribed LLT for primary or secondary prevention in primary or secondary care across Europe. Between June 2017 and November 2018, data were collected at a single visit, including LLT in the preceding 12 months and most recent LDL-C. Primary outcome was the achievement of risk-based 2016 European Society of Cardiology (ESC)/European Atherosclerosis Society (EAS) LDL-C goal while receiving stabilized LLT; 2019 goal achievement was also assessed. Overall, 5888 patients (3000 primary and 2888 secondary prevention patients) were enrolled; 54% [95% confidence interval (CI) 52–56] achieved their risk-based 2016 goal and 33% (95% CI 32–35) achieved their risk-based 2019 goal. High-intensity statin monotherapy was used in 20% and 38% of very high-risk primary and secondary prevention patients, respectively. Corresponding 2016 goal attainment was 22% and 45% (17% and 22% for 2019 goals) for very high-risk primary and secondary prevention patients, respectively. Use of moderate–high-intensity statins in combination with ezetimibe (9%), or any LLT with PCSK9 inhibitors (1%), was low; corresponding 2016 and 2019 goal attainment was 53% and 20% (ezetimibe combination), and 67% and 58% (PCSK9i combination). Conclusion: Gaps between clinical guidelines and clinical practice for lipid management across Europe persist, which will be exacerbated by the 2019 guidelines. Even with optimized statins, greater utilization of non-statin LLT is likely needed to reduce these gaps for patients at highest risk.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures





Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The DA VINCI study found that out of 5888 patients with dyslipidaemia who were enrolled in 18 European countries, only 33% achieved their risk-based LDL-C goal recommended in the European Society of Cardiology (ESC) 2019 guidelines [12].”
From Established and Emerging Lipid-Lowering Drugs for Primary and Secondary Cardiovascular Prevention (2023) · cites this paper as [12]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Mach, F., Baigent, C., Catapano, A. L., Koskinas, K. C., Casula, M., Badimon, L., Chapman, M. J., De Backer, G. G., Delgado, V., Ference, B. A., et al. (2020) · European Heart Journal · doi:10.1093/eurheartj/ehz455 · Cited by 8,961
Self-citation2016 ESC/EAS Guidelines for the Management of Dyslipidaemias
Catapano, A. L., Graham, I., De Backer, G., Wiklund, O., Chapman, M. J., Drexel, H., Hoes, A. W., Jennings, C. S., Landmesser, U., Pedersen, T. R., et al. (2016) · European Heart Journal · doi:10.1093/eurheartj/ehw272 · Cited by 3,162
Self-citationCollaborators, C. T. T. (. (2012) · The Lancet · doi:10.1016/s0140-6736(12)60367-5 · Cited by 2,833
Kotseva, K., De Backer, G., De Bacquer, D., Rydén, L., Hoes, A., Grobbee, D., Maggioni, A., Marques-Vidal, P., Jennings, C., Abreu, A., et al. (2019) · European Journal of Preventive Cardiology · doi:10.1177/2047487318825350 · Cited by 937
Wood, D. A., Backer, G. D., Graham, I., Poole-Wilson, P. A., Pyörälà, K., Shepherd, J., Zanchetti, A., Haman, P., Linhartová, K., Simon, J., et al. (1997) · Ghent University Academic Bibliography (Ghent University) · Cited by 537
EUROASPIRE Study Group (1997) · European Heart Journal · doi:10.1093/oxfordjournals.eurheartj.a015136 · Cited by 532
Nicholls, S. J., Brandrup-Wognsen, G., Palmer, M., & Barter, P. J. (2010) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2009.08.651 · Cited by 248
Ferrières, J., Ferrari, G. M. D., Hermans, M. P., Elisaf, M., Toth, P. P., Horack, M., Brudi, P., Lautsch, D., Bash, L. D., Baxter, C. A., et al. (2018) · European Journal of Preventive Cardiology · doi:10.1177/2047487318806359 · Cited by 73
Steen, D. L., Khan, I., Ansell, D., Sanchez, R. J., & Ray, K. K. (2017) · BMJ Open · doi:10.1136/bmjopen-2016-013255 · Cited by 42
Self-citationThe past, present and future of lipidlowering therapy
Najam, O., Lambert, G. C., & Ray, K. K. (2015) · Clinical Lipidology · doi:10.2217/clp.15.40 · Cited by 7
Self-citation
Cited by
2024 ESC Guidelines for the management of chronic coronary syndromes
Vrints, C., Andreotti, F., Koskinas, K. C., Rossello, X., Adamo, M., Ainslie, J., Banning, A. P., Budaj, A., Buechel, R. R., Chiariello, G. A., et al. (2024) · European Heart Journal · doi:10.1093/eurheartj/ehae177 · Cited by 2,774
2025 Focused Update of the 2019 ESC/EAS Guidelines for the management of dyslipidaemias
Mach, F., Koskinas, K. C., Roeters van Lennep, J. E., Tokgözoğlu, L., Badimon, L., Baigent, C., Benn, M., Binder, C. J., Catapano, A. L., De Backer, G. G., et al. (2025) · European Heart Journal · doi:10.1093/eurheartj/ehaf190 · Cited by 688
Self-citationNicholls, S. J., Kataoka, Y., Nissen, S. E., Prati, F., Windecker, S., Puri, R., Hucko, T., Aradi, D., Herrman, J.-P. R., Hermanides, R. S., et al. (2022) · JACC: Cardiovascular Imaging · doi:10.1016/j.jcmg.2022.03.002 · Cited by 458
Ray, K. K., Haq, I., Bilitou, A., Manu, M. C., Burden, A., Aguiar, C., Arca, M., Connolly, D. L., Eriksson, M., Ferrières, J., et al. (2023) · The Lancet Regional Health - Europe · doi:10.1016/j.lanepe.2023.100624 · Cited by 339
Self-citationPolypill strategy in secondary cardiovascular prevention
Castellano, J. M., Pocock, S. J., Bhatt, D. L., Quesada, A. J., Owen, R., Fernandez-Ortiz, A., Sanchez, P. L., Marin Ortuño, F., Vazquez Rodriguez, J. M., Domingo-Fernández, A., et al. (2022) · New England Journal of Medicine · doi:10.1056/nejmoa2208275 · Cited by 334
Metadata
- Authors
- Ray, K. K., Molemans, B., Schoonen, W. M., Giovas, P., Bray, S., Kiru, G., Murphy, J., Banach, M., De Servi, S., Gaita, D., Gouni-Berthold, I., Hovingh, G. K., Jozwiak, J. J., Jukema, J. W., Kiss, R. G., Kownator, S., Iversen, H. K., Maher, V., Masana, L., Parkhomenko, A., Peeters, A., Clifford, P., Raslova, K., Siostrzonek, P., Romeo, S., Tousoulis, D., Vlachopoulos, C., Vrablik, M., Catapano, A. L., Poulter, N. R., & study, T. D. V.
- Affiliations
- Imperial College London (GB)
- Amgen (United States) (US)
- Amgen (United Kingdom) (GB)
- Amgen Hellas, 4 Gravias Street, Maroussi, 15125, Athens, Greece
- Medical University of Lodz (PL)
- IRCCS MultiMedica, Via Milanese, 300, 20099 Sesto San Giovanni, Milan, Italy
- Institutul de Boli Cardiovasculare, Fundatia Cardioprevent, Universitatea de Medicina si Farmacie Victor Babes din Timisoara, Timişoara 300041, Romania
- Polyclinic for Endocrinology, Diabetes and Preventive Medicine, Kerpener Str. 62, 50937 Cologne, Germany
- University of Amsterdam (NL)
- University of Opole (PL)
- Leiden University Medical Center (NL)
- Hungarian Army Medical Center, Budapest, 1134, Hungary
- Centre Cardiologique et Vasculaire, 36 Route de la Briquerie, 57100, Thionville, France
- University of Copenhagen (DK)
- Trinity College Dublin (IE)
- Institut de Recerca Biomèdica Catalunya Sud (ES)
- Emergency Cardiology Department, Institute of Cardiology, Kiev, Ukraine
- Cliniques Universitaires Saint Luc, Avenue Hippocrate 10, 1200, Brussels, Belgium
- Hammersmith Hospital (GB)
- Slovak Medical University, 831 01 Bratislava, Slovakia
- Ordensklinikum Linz Barmherzige Schwestern (AT)
- Sahlgrenska University Hospital (SE)
- National and Kapodistrian University of Athens (GR)
- Charles University, Prague, 116 36 Czech Republic
- MultiMedica (IT)
- Corresponding author
- Ray, Kausik K
- ORCID
- Venue
- European Journal of Preventive Cardiology
- Publisher
- Oxford University Press (OUP)
- Published
- 2020-08-28
- Volume
- 28
- Issue
- 11
- Pages
- 1279-1289
- ISSN
- 2047-4873 (ISSN-L)
- 2047-4881
- OpenAlex
- W3120916025
- Semantic Scholar
- c6684386e0c0c350ddbd229e351fb1eb1cd4e299
- Cited by
- 839
- References
- 10
- Citations by year
- 2026: 137 · 2025: 162 · 2024: 143 · 2023: 165 · 2022: 139 · 2021: 79 · 2020: 12
- FWCI
- 90.18
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- Locations
- European Journal of Preventive Cardiology (publishedVersion, cc-by-nc)
- PubMed (publishedVersion)
- Research at the University of Copenhagen (University of Copenhagen) (publishedVersion, cc-by-nc)
- Leiden Repository (Leiden University) (submittedVersion, cc-by-nc)
- Rovira & Virgili repository (submittedVersion, cc-by)
- Data Archiving and Networked Services (DANS) (submittedVersion, other-oa)
- Data Archiving and Networked Services (DANS) (submittedVersion, cc-by-nc)
- DIAL (Catholic University of Leuven) (submittedVersion, other-oa)
- Pure Amsterdam UMC (submittedVersion, cc-by)
- Spiral (Imperial College London) (submittedVersion, cc-by-nc)
- Funders
- Amgen (Europe) GmbH
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipoproteins and Cardiovascular Health
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Blood Pressure and Hypertension Studies
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
- Keywords
- lipid-lowering therapy, LDL cholesterol goal attainment, statins, ezetimibe, PCSK9 inhibitors, guideline implementation, primary prevention, secondary prevention, very high-risk patients, non-statin therapy, cardiovascular risk management, ESC/EAS guidelines
- MeSH terms
- Proprotein Convertase 9, Anticholesteremic Agents, Cardiovascular Diseases, Cross-Sectional Studies, Humans, Cholesterol, LDL, Primary Health Care, Risk Factors, Biomarkers, Treatment Outcome, Hydroxymethylglutaryl-CoA Reductase Inhibitors, Dyslipidemias
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: EU-Wi d e Cross-Section a l Obser v at i o n al Study of Lipid-Modifying Therapy Use in Se c ondary and Pr i mary Care: the DA VINCI study. https://app.cochat.ai/papers/10.1093/eurjpc/zwaa047
- The paper
- Ray, K. K., Molemans, B., Schoonen, W. M., Giovas, P., Bray, S., Kiru, G., Murphy, J., Banach, M., De Servi, S., Gaita, D., Gouni-Berthold, I., Hovingh, G. K., Jozwiak, J. J., Jukema, J. W., Kiss, R. G., Kownator, S., Iversen, H. K., Maher, V., Masana, L., . . . study, T. D. V. (2021). EU-Wi d e Cross-Section a l Obser v at i o n al Study of Lipid-Modifying Therapy Use in Se c ondary and Pr i mary Care: the DA VINCI study. European Journal of Preventive Cardiology. https://doi.org/10.1093/eurjpc/zwaa047
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.